| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CBIC.201500565 |
| P698 | PubMed publication ID | 26684344 |
| P50 | author | Giovanna Zinzalla | Q38544637 |
| P2860 | cites work | Akirin2 is critical for inducing inflammatory genes by bridging IκB-ζ and the SWI/SNF complex | Q24301828 |
| BAF60a interacts with p53 to recruit the SWI/SNF complex | Q24317756 | ||
| CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis | Q24320341 | ||
| Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma | Q24337483 | ||
| Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling | Q24632740 | ||
| Regulation of chromatin by histone modifications | Q24635070 | ||
| Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition | Q27700161 | ||
| Structure and organization of chromatin fiber in the nucleus | Q28080958 | ||
| c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function | Q28143677 | ||
| Targeting bromodomains: epigenetic readers of lysine acetylation | Q28238635 | ||
| LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor | Q28260305 | ||
| SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 | Q28269618 | ||
| MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1 | Q28304512 | ||
| The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression | Q28508923 | ||
| An essential switch in subunit composition of a chromatin remodeling complex during neural development | Q28585238 | ||
| LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor | Q28834025 | ||
| The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation | Q30659086 | ||
| Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. | Q33725449 | ||
| The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy | Q33979793 | ||
| SWI/SNF unwraps, slides, and rewraps the nucleosome | Q34181702 | ||
| BAF60 A, B, and Cs of muscle determination and renewal | Q34316322 | ||
| Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation | Q34388531 | ||
| Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells | Q34480997 | ||
| Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement | Q34526416 | ||
| ATP-dependent chromatin remodeling: genetics, genomics and mechanisms | Q34627244 | ||
| Modelling Myc inhibition as a cancer therapy | Q34811008 | ||
| Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. | Q35087851 | ||
| Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers | Q35092542 | ||
| Finding cancer's weakest link | Q35764388 | ||
| The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies | Q36584337 | ||
| Small molecule therapeutics targeting F-box proteins in cancer | Q36600976 | ||
| Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice | Q36708046 | ||
| Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes | Q38126255 | ||
| Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 | ||
| Vulnerabilities of mutant SWI/SNF complexes in cancer. | Q38247363 | ||
| SWI/SNF chromatin remodeling and human malignancies | Q38267106 | ||
| Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. | Q38272367 | ||
| ARID1B is a specific vulnerability in ARID1A-mutant cancers. | Q38276153 | ||
| Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. | Q38339385 | ||
| Targeting protein-protein interactions (PPIs) of transcription factors: Challenges of intrinsically disordered proteins (IDPs) and regions (IDRs). | Q38540836 | ||
| FBI1/Akirin2 promotes tumorigenicity and metastasis of Lewis lung carcinoma cells | Q39030106 | ||
| Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer | Q41942526 | ||
| Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. | Q42416688 | ||
| P433 | issue | 8 | |
| P921 | main subject | drug discovery | Q1418791 |
| P304 | page(s) | 677-682 | |
| P577 | publication date | 2015-12-18 | |
| P1433 | published in | ChemBioChem | Q634395 |
| P1476 | title | A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex | |
| P478 | volume | 17 |
| Q28074465 | Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications |
| Q40093518 | Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-induced MDR1 Expression and Fluconazole Resistance |
| Q47128083 | Chemical probes and inhibitors of bromodomains outside the BET family |
| Q57281865 | Domain architecture of BAF250a reveals the ARID and ARM-repeat domains with implication in function and assembly of the BAF remodeling complex |
| Q28076548 | Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? |
| Q97653022 | Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment |
| Q49647261 | Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes |
Search more.